Results 131 to 140 of about 30,146 (272)

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Pediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella, Celina DeBiasio, Carmen Liy‐Wong   +2 more
wiley   +1 more source

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

, 2021
Alesia Khan, Claire Woodley, Deepti Radia, G. Mikhaeel, J.L. Brady, Natalia Curto‐García, Patrick Harrington, Jennifer O’Sullivan, Shahram Kordasti, Yara Nakhleh Francis, Susan Asirvatham, Sahra Ali, Priya Sriskandarajah, Jamie Saunders, Hugues de Lavallade, Donal P. McLornan, Claire Harrison   +16 more
openalex   +1 more source

43938 Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies [PDF]

, 2023
David Rosmarin, John E. Harris, Albert Wolkerstorfer, Mark Lebwohl, Khaled Ezzedine, Thierry Passeron, Deanna Kornacki, Haobo Ren, Kathleen Butler, Julien Sénéschal   +9 more
openalex   +1 more source

Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series

Transplant Infectious Disease, EarlyView.
This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...
Jenna Nunn, Ahmed Ahmed, Srividhya Senthil, Oana Mirci‐Danicar, Denise Bonney, Claire Horgan, Omima Mustafa, Robert Wynn, Malcolm Guiver, Ramya Nataraj   +9 more
wiley   +1 more source

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

Frontiers in Immunology
BackgroundUmbilical cord blood (UCB)-derived CD4+CD25+CD127low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE).
Mi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +7 more
doaj   +1 more source

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Transplant Infectious Disease, EarlyView.
Third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) were safe and effective in reducing viremia in kidney and stem cell transplant recipients with BK virus nephropathy. However, they did not improve kidney function. Earlier administration may be more beneficial before nephropathy and irreversible damage occur.
Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Valda Page, Richard E. Champlin, Dimitrios P. Kontoyiannis, Roy F. Chemaly, Elizabeth J. Shpall, Linda Moore, Osama A. Gaber, Katayoun Rezvani, Ala Abudayyeh   +18 more
wiley   +1 more source

JAK-2 inhibitors and allogeneic transplant in myelofibrosis [PDF]

, 2015
7The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce splenomegaly and symptoms in patients affected by myelofibrosis, leading to a ...
Cigana, C, De Marchi, R, Fanin, Renato, Lazzarotto, D, Patriarca, Francesca, Perali, G, Sperotto, A   +6 more
core  

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome [PDF]

, 2023
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata Monika Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michèle Cavo, Massimiliano Bonifacio, Giuseppe A. Palumbo   +39 more
openalex   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source